T regulatory cells as a potential therapeutic target in psychosis?: current challenges and future perspectives (2021)
- Authors:
- USP affiliated authors: LOUZADA JÚNIOR, PAULO - FMRP ; BEN, CRISTINA MARTA DEL - FMRP ; ZUELLI, FABIANA MARIA DAS GRAÇAS CORSI - FMRP
- Unidade: FMRP
- DOI: 10.1016/j.bbih.2021.100330
- Subjects: SISTEMA IMUNE; IMUNOLOGIA; TRANSTORNOS PSICÓTICOS; ESQUIZOFRENIA
- Keywords: Adaptive immune system; FoxP3; Interleukin-6; Psychosis; Regulatory T cells; Schizophrenia; Tregs
- Language: Inglês
- Imprenta:
- Source:
- Título: Brain, Behavior, & Immunity - Health
- ISSN: 2666-3546
- Volume/Número/Paginação/Ano: v. 17, art. 100330, p. 1-14, 2021
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
ZUELLI, Fabiana Maria das Graças Corsi et al. T regulatory cells as a potential therapeutic target in psychosis?: current challenges and future perspectives. Brain, Behavior, & Immunity - Health, v. 17, p. 1-14, 2021Tradução . . Disponível em: https://doi.org/10.1016/j.bbih.2021.100330. Acesso em: 08 jun. 2025. -
APA
Zuelli, F. M. das G. C., Deakin, B., Lima, M. H. F. de, Qureshi, O., Barnes, N. M., Upthegrove, R., et al. (2021). T regulatory cells as a potential therapeutic target in psychosis?: current challenges and future perspectives. Brain, Behavior, & Immunity - Health, 17, 1-14. doi:10.1016/j.bbih.2021.100330 -
NLM
Zuelli FM das GC, Deakin B, Lima MHF de, Qureshi O, Barnes NM, Upthegrove R, Louzada Júnior P, Del-Ben CM. T regulatory cells as a potential therapeutic target in psychosis?: current challenges and future perspectives [Internet]. Brain, Behavior, & Immunity - Health. 2021 ; 17 1-14.[citado 2025 jun. 08 ] Available from: https://doi.org/10.1016/j.bbih.2021.100330 -
Vancouver
Zuelli FM das GC, Deakin B, Lima MHF de, Qureshi O, Barnes NM, Upthegrove R, Louzada Júnior P, Del-Ben CM. T regulatory cells as a potential therapeutic target in psychosis?: current challenges and future perspectives [Internet]. Brain, Behavior, & Immunity - Health. 2021 ; 17 1-14.[citado 2025 jun. 08 ] Available from: https://doi.org/10.1016/j.bbih.2021.100330 - Antinuclear antibodies testing as a routine screening for systemic lupus erythematosus in patients presenting first-episode psychosis
- Quantification of the serum levels of NR1 and NR2 NMDA receptor in patients in the first episode psychosis
- Uso de maconha (Cannabis sativa) e perfil inflamatório em pacientes em primeiro episódio psicótico e controles de base populacional
- Parvalbumin (PVALB) promoter dna methylation association with early-life trauma in first episode psychosis patients
- Cytokine profile in first-episode psychosis, unaffected siblings and community-based controls: the effects of familial liability and childhood maltreatment
- Neutrophin brain derived neurotrophic factor (BDBF)in psychiatric systemic lupus erythematosus
- The relationship of childhood trauma and DNA methylation of NMDA receptor genes in first-episode schizophrenia
- State and trait inflammatory markers and the psychosis continuum model
- Signals of adaptive immune activation in non-clinical populations with psychotic experiences
- A randomised clinical trial of methotrexate points to possible efficacy and adaptive immune dysfunction in psychosis
Informações sobre o DOI: 10.1016/j.bbih.2021.100330 (Fonte: oaDOI API)
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
003251218.pdf | Direct link |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
